Tumor mutational burden in non-immunotherapy patients with heavily pretreated metastatic breast cancer: long-term outcomes from a single institution

References

• Cardoso F, Harbeck N, Fallowfield L, et al. Locally recurrent or metastatic breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23 (Suppl 7):vii11–9.
   PubMed Web of Science ®Google Scholar
• Johnston SRD. The role of chemotherapy and targeted agents in patients with metastatic breast cancer. Eur J Cancer. 2011;47:S38–S47.
   PubMed Web of Science ®Google Scholar
• Tanabe Y, Ichikawa H, Kohno T, et al. Comprehensive screening of target molecules by next-generation sequencing in patients with malignant solid tumors: guiding entry into phase I clinical trials. Mol Cancer. 2016;15(1):73.
   PubMedGoogle Scholar
• Wakai T, Prasoon P, Hirose Y, et al. Next-generation sequencing-based clinical sequencing: toward precision medicine in solid tumors. Int J Clin Oncol. 2019;24(2):115–122.
   PubMed Web of Science ®Google Scholar
• Elazezy M, Joosse SA. Techniques of using circulating tumor DNA as a liquid biopsy component in cancer management. Comput Struct Biotechnol J. 2018;16:370–378.
   PubMed Web of Science ®Google Scholar
• Mishima S, Kawazoe A, Nakamura Y, et al. Clinicopathological and molecular features of responders to nivolumab for patients with advanced gastric cancer. J Immunother Cancer. 2019;7(1):24.
   PubMed Web of Science ®Google Scholar
• Goodman AM, Kato S, Bazhenova L, et al. Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers. Mol Cancer Ther. 2017;16(11):2598–2608.
   PubMed Web of Science ®Google Scholar
• Park SE, Park K, Lee E, et al. Clinical implication of tumor mutational burden in patients with HER2-positive refractory metastatic breast cancer. Oncoimmunology. 2018;7(8):e1466768.
   PubMed Web of Science ®Google Scholar
• Devarakonda S, Rotolo F, Tsao MS, et al. Tumor mutation burden as a biomarker in resected non-small-cell lung cancer. J Clin Oncol. 2018; 36(30):2995–3006.
   PubMed Web of Science ®Google Scholar
• Innocenti F, Ou FS, Qu X, et al. Mutational analysis of patients with colorectal cancer in CALGB/SWOG 80405 identifies new roles of microsatellite instability and tumor mutational burden for patient outcome. JCO. 2019;37(14):1217–1227.
   PubMed Web of Science ®Google Scholar
• Owada-Ozaki Y, Muto S, Takagi H, et al. Prognostic impact of tumor mutation burden in patients with completely resected non-small cell lung cancer: Brief report. J Thorac Oncol. 2018;13(8):1217–1221.
   PubMed Web of Science ®Google Scholar
• O'Meara TA, Tolaney SM. Tumor mutational burden as a predictor of immunotherapy response in breast cancer. Oncotarget. 2021;12(5):394–400.
   PubMedGoogle Scholar
• Mustacchi G, Biganzoli L, Pronzato P, et al. HER2-positive metastatic breast cancer: a changing scenario. Crit Rev Oncol Hematol. 2015;95(1):78–87.
   PubMed Web of Science ®Google Scholar
• Hammond ME, Hayes DF, Dowsett M, et al. American society of clinical oncology/college of American pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med. 2010;134(7):e48–72.
   PubMed Web of Science ®Google Scholar
• Wolff AC, Hammond ME, Hicks DG, College of American Pathologists, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology/college of American pathologists clinical practice guideline update. J Clin Oncol. 2013;31(31):3997–4013.
   PubMed Web of Science ®Google Scholar
• McCabe MJ, Gauthier MA, Chan CL, et al. Development and validation of a targeted gene sequencing panel for application to disparate cancers. Sci Rep. 2019;9(1):17052.
   PubMedGoogle Scholar
• Keup C, Benyaa K, Hauch S, et al. Targeted deep sequencing revealed variants in cell-free DNA of hormone receptor-positive metastatic breast cancer patients. Cell Mol Life Sci. 2020;77(3):497–509.
   PubMed Web of Science ®Google Scholar
• Delgado A, Guddati AK. Clinical endpoints in oncology - a primer. Am J Cancer Res. 2021;11(4):1121–1131.
   PubMed Web of Science ®Google Scholar
• Hess LM, Brnabic A, Mason O, et al. Relationship between progression-free survival and overall survival in randomized clinical trials of targeted and biologic agents in oncology. J Cancer. 2019;10(16):3717–3727.
   PubMed Web of Science ®Google Scholar
• Endris V, Buchhalter I, Allgäuer M, et al. Measurement of tumor mutational burden (TMB) in routine molecular diagnostics: in silico and real-life analysis of three larger gene panels. Int J Cancer. 2019;144(9):2303–2312.
   PubMed Web of Science ®Google Scholar
• Hatakeyama K, Nagashima T, Urakami K, et al. Tumor mutational burden analysis of 2,000 japanese cancer genomes using whole exome and targeted gene panel sequencing. Biomed Res. 2018;39(3):159–167.
   PubMed Web of Science ®Google Scholar
• Cheng DT, Mitchell TN, Zehir A, et al. Memorial sloan Kettering-Integrated mutation profiling of actionable cancer targets (MSK-IMPACT): a hybridization Capture-Based Next-Generation sequencing clinical assay for solid tumor molecular oncology. J Mol Diagn. 2015;17(3):251–264.
   PubMed Web of Science ®Google Scholar
• Zehir A, Benayed R, Shah RH, et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med. 2017;23(6):703–713.
   PubMed Web of Science ®Google Scholar
• Chalmers ZR, Connelly CF, Fabrizio D, et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 2017;9(1):34.
   PubMed Web of Science ®Google Scholar
• Berland L, Heeke S, Humbert O, et al. Current views on tumor mutational burden in patients with non-small cell lung cancer treated by immune checkpoint inhibitors. J Thorac Dis. 2019;11(Suppl 1):S71–s80.
   PubMedGoogle Scholar
• Fang P, Yan Z, Vu Q, et al. Evaluation of a commercial targeted NGS panel for tumor mutation burden assessment in FFPE tissue. AACR; 2018.
   Google Scholar
• Zhuang W, Ma J, Chen X, et al. The tumor mutational burden of Chinese advanced cancer patients estimated by a 381-cancer-gene panel. J Cancer. 2018;9(13):2302–2307.
   PubMed Web of Science ®Google Scholar
• Budczies J, Bockmayr M, Denkert C, et al. Classical pathology and mutational load of breast cancer - integration of two worlds. J Pathol Clin Res. 2015;1(4):225–238.
   PubMedGoogle Scholar
• Visser E, Franken IA, Brosens LAA, et al. Targeted next-generation sequencing of commonly mutated genes in esophageal adenocarcinoma patients with long-term survival. Dis Esophagus. 2017;30(9):1–8.
   Web of Science ®Google Scholar
• Carbone DP, Reck M, Paz-Ares L, et al. First-line nivolumab in stage IV or recurrent non-small-cell lung cancer. N Engl J Med. 2017;376(25):2415–2426.
   PubMed Web of Science ®Google Scholar
• Burstein HJ, Lacchetti C, Anderson H, et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: ASCO clinical practice guideline focused update. J Clin Oncol. 2019;37(5):423–438.
   PubMed Web of Science ®Google Scholar
• Chan TA, Wolchok JD, Snyder A. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2015;373(20):1984.
   PubMed Web of Science ®Google Scholar
• Narang P, Chen M, Sharma AA, et al. The neoepitope landscape of breast cancer: implications for immunotherapy. BMC Cancer. 2019;19(1):200.
   PubMed Web of Science ®Google Scholar
• Iglesia MD, Vincent BG, Parker JS, et al. Prognostic B-cell signatures using mRNA-seq in patients with subtype-specific breast and ovarian cancer. Clin Cancer Res. 2014;20(14):3818–3829.
   PubMed Web of Science ®Google Scholar
• Pires ES, D'Souza RS, Needham MA, et al. Membrane associated cancer-oocyte neoantigen SAS1B/ovastacin is a candidate immunotherapeutic target for uterine tumors. Oncotarget. 2015;6(30):30194–30211.
   PubMedGoogle Scholar
• Mandili G, Mazza E, Capello M, et al. Identification of neoantigens recognized by autoantibodies in chemotherapy-treated pancreatic cancer patients. AACR; 2015.
   Google Scholar